Free Trial
NASDAQ:BWAY

BrainsWay Q1 2025 Earnings Report

BrainsWay logo
$8.71 -0.31 (-3.44%)
Closing price 05/5/2025 04:00 PM Eastern
Extended Trading
$8.68 -0.03 (-0.34%)
As of 05/5/2025 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BrainsWay EPS Results

Actual EPS
N/A
Consensus EPS
$0.02
Beat/Miss
N/A
One Year Ago EPS
N/A

BrainsWay Revenue Results

Actual Revenue
N/A
Expected Revenue
$11.45 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

BrainsWay Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Tuesday, May 13, 2025
Conference Call Time
8:30AM ET

Conference Call Resources

BrainsWay Earnings Headlines

Brainsway Ltd Sponsored ADR
Brainsway files to sell American Depositary Shares for holders
URGENT: Someone's Moving Gold Out of London...
People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “gold analysts” have it all wrong… They tell you to invest in gold ETFs - because the popular mining ETFs will someday catch fire and close the price gap with spot gold.
Brainsway sees FY25 revenue $49M-$51M, consensus $47.12M
Brainsway reports Q4 EPS 4c vs. 0c last year
See More BrainsWay Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like BrainsWay? Sign up for Earnings360's daily newsletter to receive timely earnings updates on BrainsWay and other key companies, straight to your email.

About BrainsWay

BrainsWay (NASDAQ:BWAY) develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company serves doctors, hospitals, and medical centers in the field of psychiatry. BrainsWay Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.

View BrainsWay Profile

More Earnings Resources from MarketBeat